Eli Lilly Introduces Direct Consumer Access to Zepbound

Eli Lilly has announced a new initiative to make its popular weight loss medication, Zepbound, more accessible to consumers without insurance coverage. Starting from August 27, 2024, individuals will be able to purchase Zepbound directly through the company’s pharmacy, LillyDirect, with a valid doctor’s prescription.

The company’s CEO, Dave Ricks, stated that the vials will be offered at approximately half the price of the auto-injector pre-filled pens that are typically sold at pharmacies. A one-month supply of Zepbound at a 2.5-milligram dosage will be priced at $399, while a 5-milligram supply will cost $549.

In an interview with ABC News, Ricks expressed enthusiasm about providing this new option for those seeking affordable access to Zepbound. He outlined that consumers would only need a prescription from their healthcare provider to order the medication through LillyDirect.

Starting Tuesday, medical professionals can begin filling prescriptions for the Zepbound vials, with shipping set to commence shortly thereafter. It is important to note that this new purchasing method will be self-pay only and will not engage with insurance services.

Under standard insurance coverage, Zepbound may cost as low as $25 per month. Conversely, without coverage, expenses can exceed $1,000 monthly. Through LillyDirect, customers will receive educational resources on administering the medication effectively.

Zepbound is approved by the U.S. Food and Drug Administration (FDA) for weight management in individuals classified as obese or overweight, particularly those with related health conditions, such as high blood pressure. However, many private insurers and Medicare do not provide coverage for obesity-related medications.

The active ingredient in Zepbound, tirzepatide, is also found in another Eli Lilly product, which is FDA-approved for treating Type 2 diabetes. Tirzepatide functions by encouraging the pancreas to increase insulin production, facilitating the conversion of blood sugar into body tissues. It also slows gastric emptying, reduces appetite, and promotes weight loss.

Past clinical trials indicate that individuals using weight loss drugs like Zepbound and Mounjaro may experience a weight loss ranging from 5% to 20% over an extended period. Medical professionals emphasize that utilizing medication for weight loss should be supplemented by regular cardio, strength training, and a diet rich in protein while minimizing processed foods and sugars.

Common side effects associated with weight loss medications include nausea and constipation. However, there are also reports of gallbladder and pancreatic issues. It is recommended that patients discuss the potential side effects and personalized risks with a healthcare provider prior to starting any new medication.